Indication
Treatment of congenital thrombotic thrombocytopenic purpura (cTTP) due to ADAMTS13 deficiency
Loading your page…
Loading your page…
Purpura, Thrombotic Thrombocytopenic
Marketing Authorisation Holder: Takeda Manufacturing Austria AG
EMA Authorisation: 01/08/2024
INN: rADAMTS13
AI Drug & Interaction Analysis
Free account required
Ask Osler about Adzynma: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.